



2025 Annual General Meeting Presentation

24 October 2025

LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the "Company") advises that the Annual General Meeting ("AGM") will be held today, Friday, 24 October 2025, at 2:00pm (AEST), at the offices of K&L Gates 16/66 Eagle Street, Brisbane City QLD 4000.

Attached is the AGM presentation to be delivered at the 2025 Annual General Meeting.

- ENDS -

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies for significant unmet medical needs through its proprietary intranasal drug delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.

LTR's lead products, SPONTAN® and ROXUS®, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW®, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.

For further information please contact:

Media enquiries
Haley Chartres
haley@hck.digital

Investor enquiries
Peter McLennan
investors@ltrpharma.com



Annual General Meeting

24 October 2025

AGM Presentation | October 2025

Important Notice & Disclaimer

- **Nature of Document:** This presentation has been prepared and issued by LTR Pharma Ltd (Company or LTP) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While management has taken every effort to ensure the accuracy of the material in this presentation, the Company have not verified the accuracy or completeness of the material contained in this presentation.
- **Not an offer:** This presentation is NOT a recommendation, offer or invitation to subscribe for or purchase LTP securities. This presentation is not exhaustive and does not contain all of the information a potential investor, or their professional advisers would require, and it does NOT constitute a "Prospectus" or a "Disclosure Document" (as defined in the Corporations Act 2001 (Cth), and has not been, and will not be, lodged with the Australian Securities and Investments Commission or any other regulatory authority. This presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be unlawful under the securities or other laws of that or any other jurisdiction. In particular, this presentation may not be released to US wire services or distributed publicly in the United States. See the section of this presentation captioned "International Offer Jurisdictions" for more information. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy any securities in any jurisdiction. Any failure to comply with such restrictions could constitute a violation of applicable securities laws.
- **Not financial product advice:** You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision.
- **Forward looking statements:** This presentation contains forward-looking information about the Company and its operations. In certain cases, forward-looking information may be identified by such terms as "anticipates", "believes", "should", "could", "estimates", "target", "likely", "plan", "expects", "may", "intend", "shall", "will", or "would". These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements.
- **Disclaimer:** No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any effort or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice.

• LTR Pharma Limited ACN 644 924 569

A transformative year of clinical and commercial success

Australian Financial Year

Q1 2024/25

SPONTAN prescribed to first patient under TGA

Co-development agreement signed with Aptar Pharma

Q2 2024/25

Online JV Platform launch

SPONTAN final study results demonstrating 5 x faster absorption

Men's Health Pharmacy Distribution Agreement

Q3 2024/25

ROXUS Development initiation

Symbion National Pharmacy Distribution Agreement

SPONTAN FDA pre-IND meeting completed

Q4 2024/25

OROFLOW agreement signed

SPONTAN Extractables Study completed

Q1 2025/26

US-based ED specialists join Advisory board

SPONTAN demonstrates strong Post-Prostatectomy Results

LTR Pharma secures 43% of LevOmega

Investment Highlights

LTR Pharma positioned in a clear gap in the market



Diversified Commercial Strategy Reducing Risk

- SPONTAN® active in Australia via SAS
- ROXUS® targeting US personalised medicine H1 CY2026
- Regulatory approvals expanding market access



Compelling pivotal pharmacokinetic study data

- 5x faster absorption than oral tablets



Blockbuster market with issues

- Existing PDE5 inhibitors have a high discontinuation rate due to poor efficacy and side effects



Blue chip partners

- Aptar Pharma: Strategic Co-development partner - Nasdaq listed;
- Mayne Pharma: Commercial manufacturing partner (CMO) - ASX listed
- Symbion – Australian distributor, owned by ASX listed EBOS Group



Multiple upcoming milestones

- SPONTAN Phase II PK Study
- ROXUS® development completed
- ROXUS launch H1 CY 2026
- Growing Online Prescribing
- SPONTAN Animal Tox Study
- Published data
- Partnership discussions
- OROFLOW® development for OMD

Understanding the Market Need

A significant healthcare challenge affecting relationships and quality of life



50% Stop purchasing PDE5 tablets¹



60% Of men over 45 experience ED²




Growing prevalence with age impacts quality of life

Physical causes

- Heart Health
- Prostate Health
- Diabetes
- Medical Treatments
- Hair loss
- Weight loss
- Antidepressants

Psychological Impact

- Relationship problems
- Mental Wellbeing
- Day to day stress



Prevalence of ED with individuals with cardiovascular risk factors, hypertension and diabetes, is reported as high as 50%

Global Market Need


ED can impact physical and psychological health

Global ~322m men by 2025



Estimated Market size

Forecast to be US\$6.0B market by 2028



Online sales expansion

Majority of ED medication is now sold through online channels

Current Treatments

Oral PDE5 inhibitors & SPONTAN® Nasal Spray

Oral Phosphodiesterase-5 (PDE5) inhibitors are first-line treatments

Product	Main Brand(s)	Time before sexual activity for dose	Approval Date (US)	Generic availability
Sildenafil	Viagra	1 hour+	1998	Yes
Tadalafil	Cialis	1 hour+	2003	Yes
Varendafil	Levitra, Staxyn	1 hour+	2003	Yes
Avanafil	Stendra	30 minutes+	2012	No

Issues with oral PDE5 inhibitors



Does not work for 30-35% of patients



Long response time of 1 hour + affects spontaneity



Adverse reactions in up to 35% of patients

= High discontinuation rate



SPONTAN

First and only PDE5 nasal spray, available now in Australia under TGA early access.

SPONTAN® The Science of Superior Delivery

Faster and More Potent



Speed Superiority

- ▶ Tmax: 5 x faster than oral tablets
- ▶ Peak concentration in as little as 9 mins
- ▶ Average onset: 12 mins vs 56 mins



Potency Advantage

- ▶ Half the dose
- ▶ Dose-normalised Cmax is 155.6% higher than orals
- ▶ Consistent effectiveness
- ▶ Direct bloodstream delivery bypasses liver metabolism



Proven Safety

- ▶ Validated safety profile
- ▶ No severe events
- ▶ Clinically proven

Healthcare Professional Insight

Patients can respond in **as little as 5 minutes**, well before peak concentration is reached*


*Based on healthcare professional feedback



Time to peak concentration (Tmax) (minutes)

SPONTAN


Tablets



Making headlines in FY25


Throughout FY25, LTR Pharma maintained a strong media presence across Ausbiz, The Australian, The West Australian, and Medical Forum, reinforcing SPONTAN awareness and commercial progress.

The Company's Conversation Series expanded with expert-led content from Dr Thomas Silva and sexual health counsellor Melissa Hadley Barrett, establishing LTR as a thought leader in erectile dysfunction.



Company History

Progressed company substantially derisking the proposition



Board of Directors

Seasoned leadership driving innovation and growth in healthcare



Mr. LEE RODNE
(Executive Chairman)

- ▲ 25 years in healthcare and tech sectors in both public ASX and private enterprises.
- ▲ Led a healthcare spin-out from ASX Fortescue Metals Group (Allied Medical, Admedus Ltd)
- ▲ Worked with Professor Ian Frazer on advancing therapeutic vaccines into clinical studies

Track record of commercialising medical devices in Australia, North America, Europe and Asia with significant experience in Nasal Spray product sales

Ms. MAJA MCGUIRE
(Independent Non-Executive Director)

- ▲ 15 years of experience providing corporate and compliance advice to ASX-listed public companies as an Australian-qualified lawyer.
- ▲ This includes working with listed companies as a non-executive director, general counsel, company secretary and in private practice.
- ▲ Current Non-Executive Chair of ASX-listed TechGen Metals (ASX: TG1), non-executive director of Kuniko (ASX: KNI) and non-executive director of Indiana Resources Limited (ASX: IDA).

Dr. JULIAN CHICK
(Independent Non-Executive Director)

- ▲ 20 years of experience in senior management and board positions, including in ASX-listed companies Avexa Ltd, Admedus Ltd, and current CEO of ReNerve Ltd (ASX: RNV and current director of MABT Ltd and LTR Medical Ltd.
- ▲ Over 8 years of experience in investment banking and reviewing healthcare and biotechnology investment opportunities for private equity investors and venture capitalists.

Global Team, Strategic US Presence

Experienced leadership across key markets

Executive Chairman | Lee Rodne

25 years in healthcare and tech sectors in both public ASX and private enterprises.

Chief Finance Officer | Jacques Shipper

18 years of experience in Finance, Commercial Management and Controller roles.

Chief Operating Officer | Peter McLennan

18 years of experience in investment banking, investor relations and operations.

Chief Medical Officer | Prof Geoffrey Strange

20 years of experience in the Pharmaceutical and medical industries as a Senior Executive and Medical Researcher.

Chief Commercial Officer | Danny Zanardo

25 years of commercial experience in the Australian and global healthcare sectors across pharmaceuticals and medical devices.

Program Director | Anthony Bishop

30 years experience in all aspects of pharmaceutical, medical device and diagnostic development for global markets

General Manager & Business Development US | Tom Riester

25 years experience in sales and management in digital health, medical device and precision medicine.

Vice President – US Sales & Marketing | Mike Sweeting

30 years in the Pharmaceutical industry in US commercial sales and Market Access.

Vice President Operations & Clinical Development | Dr Monil Shah

20 years of Pharmaceutical and biotechnology industry experience in drug development.

Vice President, Global Regulatory Affairs | Kip Vought

25 years across global markets - Senior Pharmaceutical R&D and regulatory executive.

US TEAM

2025-2026 Key Milestones

Calendar Year

Q4 2025	Q1 2026	H1 2026	2026 Additional Activities
Animal Tox study commencement	Phase II enrolment	ROXUS 1st US Sales	Published data
	PK study enrolment	Phase II completion and data read out	Partnerships discussions
	Human factor study completion		TGA pathway
			OROFLOW development

Corporate Structure

ASX Code

LTP

Shares on issue	181.61M
Market Capitalisation	A\$96M
Cash and cash equivalents (30 June 2025)	A\$31.84M
Top 20 shareholder percentage	43.25%

As of 23 October 2025